Literature DB >> 28866757

Levels of amyloid-beta-42 and CSF pressure are directly related in patients with Alzheimer's disease.

Tommaso Schirinzi1,2, Giulia Di Lazzaro3, Giulia Maria Sancesario4, Vito Luigi Colona3, Eugenia Scaricamazza3, Nicola Biagio Mercuri3,4, Alessandro Martorana3, Giuseppe Sancesario3.   

Abstract

Experimental data suggest that the cerebrospinal fluid (CSF) dynamic is involved in the clearance of beta-amyloid, a key event in the pathogenesis of Alzheimer's disease (AD). At this regard no evidence still exists in vivo. In this study we explored the relationships between CSF pressure and AD pathology, as measured with CSF core biomarkers. We enrolled 16 patients with probable AD and 21 controls, collecting demographics, clinical data, CSF opening pressure and CSF levels of beta-amyloid-42 fragment (Aβ42), total-tau (t-tau), phosphorylated-tau-181 (p-tau), albumin and albumin ratio. Differences between the groups were calculated with non-parametric tests, while correlations among all parameters were separately calculated with Spearman's test in each group. The groups significantly differed in biomarkers' concentration with lower Aβ42, and higher t-tau and p-tau in AD patients. Moreover, CSF pressure was significantly lower in AD group (11.0 ± 2.8 vs. 13.3 ± 3.0 mmHg, p < 0.05) and directly correlated with Aβ42 levels (R = 0.512; p < 0.05), but not with other biomarkers or parameters. No significant correlations emerged for biomarkers in control group. AD patients exhibit low CSF pressure whose values are directly and selectively related to CSF Aβ42 levels. This interesting correlation may confirm in vivo the association between CSF dynamic and beta-amyloid metabolism occurring in AD.

Entities:  

Keywords:  Alzheimer’s disease; Amyloid; Amyloidopathy; CSF biomarkers; CSF pressure; Glymphatic system

Mesh:

Substances:

Year:  2017        PMID: 28866757     DOI: 10.1007/s00702-017-1786-8

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  32 in total

1.  The cerebrospinal fluid production rate is reduced in dementia of the Alzheimer's type.

Authors:  G D Silverberg; G Heit; S Huhn; R A Jaffe; S D Chang; H Bronte-Stewart; E Rubenstein; K Possin; T A Saul
Journal:  Neurology       Date:  2001-11-27       Impact factor: 9.910

2.  Capillary and arterial cerebral amyloid angiopathy in Alzheimer's disease: defining the perivascular route for the elimination of amyloid beta from the human brain.

Authors:  S D Preston; P V Steart; A Wilkinson; J A R Nicoll; R O Weller
Journal:  Neuropathol Appl Neurobiol       Date:  2003-04       Impact factor: 8.090

3.  Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes.

Authors:  Linda J C van Waalwijk van Doorn; Juan D Gispert; H Bea Kuiperij; Jurgen A H R Claassen; Andrea Arighi; Inês Baldeiras; Kaj Blennow; Marco Bozzali; Miguel Castelo-Branco; Enrica Cavedo; Derya D Emek-Savaş; Erden Eren; Paolo Eusebi; Lucia Farotti; Chiara Fenoglio; Juan Fortea Ormaechea; Yvonne Freund-Levi; Giovanni B Frisoni; Daniela Galimberti; Sermin Genc; Viviana Greco; Harald Hampel; Sanna-Kaisa Herukka; Yawu Liu; Albert Lladó; Alberto Lleó; Flavio M Nobili; Kader K Oguz; Lucilla Parnetti; João Pereira; Agnese Picco; Maria Pikkarainen; Catarina Resende de Oliveira; Esen Saka; Nicola Salvadori; Raquel Sanchez-Valle; Isabel Santana; Elio Scarpini; Philip Scheltens; Hilkka Soininen; Roberto Tarducci; Charlotte Teunissen; Magda Tsolaki; Andrea Urbani; Eduard Vilaplana; Pieter Jelle Visser; Asa K Wallin; Görsev Yener; José L Molinuevo; Olga Meulenbroek; Marcel M Verbeek
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

Review 4.  Clearance systems in the brain-implications for Alzheimer disease.

Authors:  Jenna M Tarasoff-Conway; Roxana O Carare; Ricardo S Osorio; Lidia Glodzik; Tracy Butler; Els Fieremans; Leon Axel; Henry Rusinek; Charles Nicholson; Berislav V Zlokovic; Blas Frangione; Kaj Blennow; Joël Ménard; Henrik Zetterberg; Thomas Wisniewski; Mony J de Leon
Journal:  Nat Rev Neurol       Date:  2015-07-21       Impact factor: 42.937

Review 5.  Neurovascular defects and faulty amyloid-β vascular clearance in Alzheimer's disease.

Authors:  Abhay P Sagare; Robert D Bell; Berislav V Zlokovic
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

6.  Amyloid-β-dependent compromise of microvascular structure and function in a model of Alzheimer's disease.

Authors:  Adrienne Dorr; Bhupinder Sahota; Lakshminarayan V Chinta; Mary E Brown; Aaron Y Lai; Keran Ma; Cheryl A Hawkes; JoAnne McLaurin; Bojana Stefanovic
Journal:  Brain       Date:  2012-10       Impact factor: 13.501

7.  Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children.

Authors:  Deborah I Friedman; Grant T Liu; Kathleen B Digre
Journal:  Neurology       Date:  2013-08-21       Impact factor: 9.910

Review 8.  Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseases-From pathophysiology to clinical practice.

Authors:  Kaj Blennow; Leonardo Biscetti; Paolo Eusebi; Lucilla Parnetti
Journal:  Mov Disord       Date:  2016-05-04       Impact factor: 10.338

Review 9.  Regulation of cerebrospinal fluid (CSF) flow in neurodegenerative, neurovascular and neuroinflammatory disease.

Authors:  Matthew J Simon; Jeffrey J Iliff
Journal:  Biochim Biophys Acta       Date:  2015-10-22

10.  Vascular and parenchymal amyloid pathology in an Alzheimer disease knock-in mouse model: interplay with cerebral blood flow.

Authors:  Hongmei Li; Qinxi Guo; Taeko Inoue; Vinicia A Polito; Katsuhiko Tabuchi; Robert E Hammer; Robia G Pautler; George E Taffet; Hui Zheng
Journal:  Mol Neurodegener       Date:  2014-08-09       Impact factor: 14.195

View more
  8 in total

1.  Association between physical activity and dementia's risk factors in patients with Parkinson's disease.

Authors:  Mohammad Alwardat; Tommaso Schirinzi; Giulia Di Lazzaro; Giulia Maria Sancesario; Donatella Franco; Paola Imbriani; Paola Sinibaldi Salimei; Sergio Bernardini; Nicola Biagio Mercuri; Antonio Pisani
Journal:  J Neural Transm (Vienna)       Date:  2019-02-12       Impact factor: 3.575

2.  Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy.

Authors:  Tommaso Schirinzi; Giulia Maria Sancesario; Giulia Di Lazzaro; Simona Scalise; Vito Luigi Colona; Paola Imbriani; Nicola Biagio Mercuri; Sergio Bernardini; Anthony E Lang; Antonio Pisani
Journal:  J Neural Transm (Vienna)       Date:  2018-06-14       Impact factor: 3.575

Review 3.  Insulin resistance and impaired lipid metabolism as a potential link between diabetes and Alzheimer's disease.

Authors:  Joshua A Kulas; Thaddeus K Weigel; Heather A Ferris
Journal:  Drug Dev Res       Date:  2020-02-05       Impact factor: 4.360

Review 4.  Diagnosis of neurodegenerative dementia: where do we stand, now?

Authors:  Giulia M Sancesario; Sergio Bernardini
Journal:  Ann Transl Med       Date:  2018-09

5.  Tau and Amyloid-β Peptides in Serum of Patients With Parkinson's Disease: Correlations With CSF Levels and Clinical Parameters.

Authors:  Tommaso Schirinzi; Henri Zenuni; Piergiorgio Grillo; Roberta Bovenzi; Gisella Guerrera; Francesca Gargano; Massimo Pieri; Sergio Bernardini; Nicola Biagio Mercuri; Luca Battistini; Giulia Maria Sancesario
Journal:  Front Neurol       Date:  2022-02-25       Impact factor: 4.003

Review 6.  Research on the Glial-Lymphatic System and Its Relationship With Alzheimer's Disease.

Authors:  Danhua Ding; Xinyu Wang; Qianqian Li; Lanjun Li; Jun Wu
Journal:  Front Neurosci       Date:  2021-06-16       Impact factor: 4.677

7.  Association of Difference in Coronary Sinus Diameter by Computed Tomographic Angiography Between Patients in and Not in Stable Atherosclerotic Plaque(S).

Authors:  Yancui Li; Wen Liang; Jianchun Zhang; Ruchen Peng
Journal:  Med Sci Monit       Date:  2018-05-18

8.  Comparison of the Efficacy, Side Effects, and Cost of Modafinil and Intranasal Mometasone Furoate in Obstructive Sleep Apnea-Hypopnea Syndrome: A Preliminary Clinical Study.

Authors:  Shujia Zhang; Jing Fu; Zhongnin Duan
Journal:  Med Sci Monit       Date:  2018-05-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.